Connective Tissue Diseases in Pregnancy

Authored by , Reviewed by Dr John Cox | Last edited | Meets Patient’s editorial guidelines

Added to Saved items
This page has been archived. It has not been updated since 29/08/2014. External links and references may no longer work.
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Hypermobility Syndrome article more useful, or one of our other health articles.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Connective tissue is the structure that holds the body together and is composed largely of collagen and elastin. Connective tissue disorders are classified into a number of groups. The significance of pregnancy varies considerably according to the type of the disease:

The hereditary forms tend to manifest fairly early in life. They are not often apparent at birth but are usually diagnosed before the advent of reproduction. The autoimmune forms tend to present after the reproductive years but it is not at all uncommon for them to present before middle age. Reproductive problems may be the presenting feature.

  • The HCTDs are usually inherited in a typical Mendelian form as autosomal dominant. Males and females are equally affected.
  • The autoimmune diseases are acquired rather than inherited but they do tend to run in families. The exact aetiology is uncertain but if there is an external trigger, it would appear that a genetic predisposition is involved.
  • The conditions are more common in women.
  • For the hereditary forms, genetic counselling is important, ideally before the woman becomes pregnant.

Ehlers-Danlos syndrome

The risk varies considerably according to the type of the condition:

  • Obstetric complications include risk of uterine rupture during labour, damage to the vagina and perineum, bleeding and rupture of blood vessels and the colon during the puerperium.[1]
  • In type IV there is a risk for severe bleeding and vessel rupture associated with pregnancy.[2]
  • In type II a Shirodkar's suture may be required to treat cervical incompetence.[3]
  • Generally Ehlers-Danlos syndrome is well tolerated in pregnancy except for type IV.

Marfan's syndrome

  • The major risk for women with Marfan's syndrome is aortic dissection in pregnancy. Family history may indicate the level of this risk but echocardiography to assess the aortic root in pregnancy should be used.
  • Aortic dissection is not the only problem and a multidisciplinary approach is recommended.[4]
  • Surgery may be required before embarking on pregnancy. Aortic repair can be performed during pregnancy.
  • Beta-blockers may be protective although they are associated with the risk of low birth-weight babies.[5]

Pseudoxanthoma elasticum (PXE)

  • PXE is characterised by degeneration of elastic tissue. Clinically, its effects are most readily noted in the skin, retina, blood vessels, and myocardium.
  • It is not associated with particularly increased fetal loss or adverse outcomes. A few pregnancies are associated with worsening of skin manifestations.[6]
  • The incidence of gastric bleeding is probably higher than in the unaffected population.
  • Retinal complications are uncommon.

As well as any effects caused directly by the connective tissue disorder, the woman may be taking drugs for the condition and these may be teratogenic - eg, methotrexate which induces abortion. The relative risks and benefits of the various drugs in pregnancy need to be carefully weighed.

Fetal loss

  • The risk of fetal loss is much higher than in the general population and this is particularly marked in those with SLE or a component of the disease in their connective tissue disease disorder.
  • The highest risk of all comes with those with antiphospholipid antibodies, and the problem of pregnancy is discussed in the separate article on Antiphospholipid Syndrome. Not only is there a high incidence of miscarriage in the first trimester, but there is a significant risk of intrauterine death in the second and third trimesters.

In women with SLE the acronym 'PATH' represents:

  • Proteinuria.
  • Antiphospholipid syndrome.
  • Thrombocytopenia.
  • Hypertension early in pregnancy.

All of these are serious risk factors for adverse pregnancy outcomes.[7]

Fertility is normal and pregnancy is safe in mild or stable SLE. In severe SLE, pregnancy should be delayed until the disease is better controlled. See also the separate article on Systemic Lupus Erythematosus.

  • Women with rheumatoid arthritis (RA) have fewer children than average but this appears to be a conscious decision related to the difficulty of rearing children, with the limitations of the disease, rather than problems of fecundity.[8]
  • However, a survey of American women with SLE and RA found that:[9]
    • Hypertensive disorders of pregnancy occurred in 23.2% of those with SLE and 11.1% of those with RA compared with 7.8% of the general population.
    • They tended to have more caesarean sections and longer stays in hospital.
    • They also tended to be older than the general population having babies but this did not account for the difference.
  • In women with stable SLE, the use of oral contraceptives does not increase the risk of flare-up.[10]

Further reading and references

  1. Erez Y, Ezra Y, Rojansky N; Ehlers-Danlos type IV in pregnancy. A case report and a literature review. Fetal Diagn Ther. 200823(1):7-9. Epub 2007 Oct 9.

  2. Combeer EL, Combeer AD; A rare cause of maternal death: liver and inferior vena cava rupture due to Eur J Anaesthesiol. 2008 Sep25(9):765-7. Epub 2008 Apr 10.

  3. Ploeckinger B, Ulm MR, Chalubinski K; Ehlers-Danlos syndrome type II in pregnancy. Am J Perinatol. 1997 Feb14(2):99-101.

  4. Bowater SE, Thorne SA; Management of pregnancy in women with acquired and congenital heart disease. Postgrad Med J. 2010 Feb86(1012):100-5.

  5. Montan S; Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol. 2004 Apr16(2):111-5.

  6. Bercovitch L, Leroux T, Terry S, et al; Pregnancy and obstetrical outcomes in pseudoxanthoma elasticum. Br J Dermatol. 2004 Nov151(5):1011-8.

  7. Clowse ME, Magder LS, Witter F, et al; Early risk factors for pregnancy loss in lupus. Obstet Gynecol. 2006 Feb107(2 Pt 1):293-9.

  8. Katz PP; Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum. 2006 Apr 1555(2):217-23.

  9. Chakravarty EF, Nelson L, Krishnan E; Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006 Mar54(3):899-907.

  10. Petri M, Kim MY, Kalunian KC, et al; Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15353(24):2550-8.